Taken together, the association of chemerin and CMKLR1 with ovarian cancer prognosis seems to be complex, and factors such as hormonal status or comorbidities such as adiposity, dyslipidemia, or hypertension must be considered. Here, RARRES2 is linked to metabolic syndrome.